Immune Dysregulation as a Driver of Coronary Heart Disease
- 1School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
- 2Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China
Abstract
Coronary heart disease (CHD) affects millions of individuals worldwide and remains a leading cause of morbidity and mortality. It compromises quality of life primarily through myocardial ischemia resulting from progressive coronary arterial narrowing and contributes to a wide range of adverse clinical outcomes. Although current therapeutic strategies, including coronary revascularization, lipid-lowering therapy, and plaque stabilization, have substantially improved patient prognosis, they do not fully address the underlying immunopathological mechanisms driving disease progression. Increasing evidence suggests that immune-mediated inflammation and vascular injury play critical roles in the initiation, progression, and destabilization of atherosclerotic plaques, highlighting the immune system as a potential therapeutic target in CHD management. In this review, we summarize recent advances in our understanding of the contributions of innate and adaptive immune responses to CHD pathogenesis. Collectively, current evidence indicates that immune dysregulation is a central driver of atherogenesis and its clinical manifestations, supporting the development of targeted immunomodulatory strategies as promising approaches for the prevention and treatment of CHD.
Related
- Serum brain-derived neurotrophic factor response to maximal exercise in coronary artery disease and chronic heart failure
- Implementing a Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease in a Diverse Cohort
- Cross‐tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease
- Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
- Regional Validation of Coronary Heart Disease Risk Factors in Psoriasis: A Multicenter Study in Southern China
BibTeX
@article{chu2026immune,
title = {{Immune Dysregulation as a Driver of Coronary Heart Disease}},
author = {Sijie Chu and Huifen Zhou and Haitong Wan},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209149},
url = {https://www.mdpi.com/1422-0067/27/20/9149},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immune Dysregulation as a Driver of Coronary Heart Disease
AU - Sijie Chu
AU - Huifen Zhou
AU - Haitong Wan
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209149
UR - https://www.mdpi.com/1422-0067/27/20/9149
AB - Coronary heart disease (CHD) affects millions of individuals worldwide and remains a leading cause of morbidity and mortality. It compromises quality of life primarily through myocardial ischemia resulting from progressive coronary arterial narrowing and contributes to a wide range of adverse clinical outcomes. Although current therapeutic strategies, including coronary revascularization, lipid-lowering therapy, and plaque stabilization, have substantially improved patient prognosis, they do not fully address the underlying immunopathological mechanisms driving disease progression. Increasing evidence suggests that immune-mediated inflammation and vascular injury play critical roles in the initiation, progression, and destabilization of atherosclerotic plaques, highlighting the immune system as a potential therapeutic target in CHD management. In this review, we summarize recent advances in our understanding of the contributions of innate and adaptive immune responses to CHD pathogenesis. Collectively, current evidence indicates that immune dysregulation is a central driver of atherogenesis and its clinical manifestations, supporting the development of targeted immunomodulatory strategies as promising approaches for the prevention and treatment of CHD.
SN - 1422-0067
ER -